Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

NCT00896532 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

419

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Bone Mineral Density
Postmenopausal Osteoporosis

Interventions

DRUG: Placebo to Romosozumab
DRUG: Alendronate
DRUG: Teriparatide
DRUG: Romosozumab
DRUG: Denosumab
DRUG: Placebo to Denosumab
DRUG: Zoledronic acid

Sponsor

Amgen